Takehito Shukuya

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.

Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.

Journal: Thoracic cancer

Published: March 14, 2026

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 26, 2026

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 29, 2026

Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report.

Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 05, 2025

Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.

Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 31, 2025

Advances in Pharmacological Treatment of Thoracic Malignancies.

Advances in Pharmacological Treatment of Thoracic Malignancies.

Journal: Juntendo medical journal

Published: October 28, 2025

Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.

Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.

Journal: Clinical lung cancer

Published: September 12, 2025

Intrapleural Administration of Hypotonic Cisplatin for Patients With Malignant Pleural Effusions and Non-Expandable Lungs.

Intrapleural Administration of Hypotonic Cisplatin for Patients With Malignant Pleural Effusions and Non-Expandable Lungs.

Journal: Thoracic cancer

Published: June 24, 2025

Development of a multimodal fully automated ensemble model to predict EGFR mutation and efficacy of EGFR-TKI in non-small cell lung cancer.

Development of a multimodal fully automated ensemble model to predict EGFR mutation and efficacy of EGFR-TKI in non-small cell lung cancer.

Journal: Translational lung cancer research

Published: June 08, 2025

Comparative analysis of the tumor immune microenvironment between thymoma and thymic carcinoma.

Comparative analysis of the tumor immune microenvironment between thymoma and thymic carcinoma.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 03, 2025

Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer.

Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: May 31, 2025

Spontaneous regression of tumors post-chemotherapy in a patient with relapsed small cell lung cancer: a case report.

Spontaneous regression of tumors post-chemotherapy in a patient with relapsed small cell lung cancer: a case report.

Journal: Translational lung cancer research

Published: May 17, 2025

Showing 1-12 of 133

Last Updated: 09/26/2026